IFX-1

Phase II Active

A complement C5a inhibitor potentially for the treatment of sepsis, systemic inflammatory response syndrome and inflammation.

Research Code CaCP-29; IFX-1

CAS No.

Interferon-alpha-n3

(Alferon, Naturaferon^®) Approved

An interferon α-n3 potentially for the treatment of human papillomavirus infections.

Research Code

CAS No.

Follitropin alfa biosimilar (Allergan/Itero Biopharmaceuticals)

Phase III Active

A recombinant follicle stimulating hormone potentially for the treatment of female infertility.

Research Code

CAS No. 146479-72-3 (Follitropin alfa)

Muromonab CD3 oral (Therapix Biosciences)

Phase II Discontinued

A CD3 targeted antibody potentially for the treatment of hepatitis C, non-alcoholic steatohepatitis, type 1 diabetes mellitus and ulcerative colitis.

Research Code aCD-3; aCD-3-MAb;OKT-3-oral-NasVax; Oral-anti-CD3-MAb; TRX-318

CAS No.

DLBS-2411

Phase III Active

A proton pump inhibitor (PPI) potentially for the treatment of peptic ulcer.

Research Code DLBS-2411

CAS No.

AB-16B5

Phase I Active

A clusterin targeted antibody potentially for the treatment of solid tumours.

Research Code AB-16B5; 16B5; AB-sCLU mAB

CAS No.

Recombinant lactoferrin (Ventria Bioscience)

Phase II Active

A recombinant human lactoferrin potentially for the treatment of inflammation.

Research Code VEN-100; VEN-101; VEN-120; VEN-130; VEN-140; VEN-150

CAS No.

AMP-224

Phase I Active

A programmed death receptor-1 (PD-1) blocker potentially for the treatment of colorectal cancer.

Research Code 2661380; AMP-244; GSK-2661380

CAS No.

PRX-003

Phase I Active

A cell adhesion molecule inhibitor potentially for the treatment of psoriasis.

Research Code PRX-003

CAS No.

Diperdipine

Phase II Discontinued

A calcium channel antagonist potentially for the treatment of angina pectoris and hypertension.

Research Code YS-201

CAS No. 108852-42-2(YS-201)

Recombinant human ErbB3 fragment vaccine (Zensun)

Phase I Active

A vaccine potentially for the treatment of cancer.

Research Code rhErbB3-f

CAS No.

Polyadenylic polyuridylic acid

NDA Filing Pending

An immunostimulant potentially for the treatment of breast cancer.

Research Code BN-52101

CAS No.

Factor IX long-acting (OPKO Health)

Phase I Pending

A long-acting factor IX potentially for the treatment of haemophilia B.

Research Code Factor IX-CTP; FIX-CTP; MOD-9017

CAS No.

Factor VIIa-CTP

Phase II Active

A long-acting factor VIIa-CTP fusion protein potentially for the treatment of haemophilia.

Research Code MOD-5014; MOD-5017

CAS No.

Recombinant human neuregulin-1

(Neucardin^®) Active

A recombinant human neuregulin-1 β potentially for the treatment of chronic heart failure.

Research Code rhNRG-1

CAS No.

Sotatercept

Phase II Active

A ActRIIA-Fc fusion protein potentially for the treatment of anaemia, β-thalassaemia, renal osteodystrophy and vascular calcification.

Research Code ACE-011; RAP-011

CAS No.

TZ-101

Phase II Active

A human recombinant enzyme α-1,3 fucosyltransferase VI potentially for the treatment of graft-versus-host disease and haematological malignancies.

Research Code TZ-101; ASC-101

CAS No. 9033-08-3

ABI-H0731

Phase I Active

A viral core protein modulator potentially for the treatment of HBV infection.

Research Code ABI-H0731

CAS No.

Dornase alfa biobetter (Pharmsynthez/Xenetic Biosciences)

(PulmoXen, Bronchozym^®) Phase I Active

A recombinant DNase enzyme potentially for the treatment of cystic fibrosis.

Research Code PSA-DNase

CAS No.

Glatiramer acetate liposomal (Pharmsynthez/Xenetic Biosciences)

(MyeloXen^®) Phase II Pending

A liposomal formulation of glatiramer acetate vaccine potentially for the treatment of multiple sclerosis.

Research Code

CAS No.